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SIGNALING CHARACTERIZATION OF UP-REGULATION OF MOUSE AND 
HUMAN BILE SALT EXPORT PUMP (BSEP) EXPRESSION BY BERBERINE 
 






 Bile salt export pump (Bsep) is primarily responsible for biliary excretion of bile 
salts in the liver. Genetic mutation or drug-induced dysfunction of Bsep often leads to 
disruption of enterohepatic circulation of bile acids and consequently cholestatic liver 
injury. Berberine (BBR), a traditional herbal medicine, promotes bile flow and has been 
suggested to treat liver diseases, including cholestasis. We recently reported that BBR 
induces Bsep expression in mouse liver. However, the underlying mechanism by which 
BBR induces Bsep expression is unknown. My dissertation project showed that BBR 
induced mouse and human Bsep/BSEP mRNA and protein expression. In addition, BBR 
increased Bsep/BSEP transport activity, evidenced by increased cellular efflux of 
dichlorofluorescin diacetate, a selective Bsep substrate. BBR activated NRF2 signaling in 
human hepatoma cells, which contributed to BBR-induced human BSEP expression. 
However, activation of Nrf2 signaling was not essential for induction of mouse Bsep by 
BBR because BBR continued to increase Bsep expression in Nrf2-null mouse liver and 
Nrf2-silenced mouse hepatoma cells. In addition, BBR reversed LPS-decreased mouse 
Bsep expression in both mouse liver and cultured mouse hepatoma cells. Mechanistically, 
BBR attenuated LPS-activated TLR4-NF-кB signaling, which may contribute to BBR-
induced mouse Bsep expression. In conclusion, BBR induced human BSEP expression 
through NRF2 activation; whereas BBR induced mouse Bsep expression most likely 
through TLR4 inhibition.    
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CHAPTER 1 INTRODUCTION 
1. Overview 
        Cholestasis is liver disease with impaired bile flow, primarily caused by impaired 
hepatic secretion or biliary obstruction (Reichen et al., 1994). Occurrence of cholestasis 
is increasing in prevalence worldwide (Beste et al., 2015; Asrani, et al., 2013, 2019). 
Current research on cholestasis primarily focuses on the characterization of mechanisms 
by which cholestasis is produced, and the investigation of effective therapies to attenuate 
the progression of cholestasis. We have previously reported that berberine (BBR), a 
traditional herbal medicine historically used to treat bacterial infections, promote bile 
flow and increase expression and transport function of Na+-taurocholate cotransporting 
polypeptide (Ntcp), the major liver bile acid uptake transporter , by inhibiting Jak2-Stat5 
signaling (Bu et al., 2017). During this study, we also found that BBR induces mRNA 
expression of bile salt export pump (Bsep), the major liver bile acid efflux transporter, in 
mouse liver. The results of my dissertation project further demonstrated that BBR 
induces expression of mouse and human Bsep/BSEP transporter gene through different 
mechanisms.  
        In Chapter 1, the current understanding and ongoing research of traditional herbal 
medicine BBR, including its pharmaceutical applications, pharmacokinetics, and 
toxicological profiles are reviewed. In addition, the function and regulation of Bsep 
transporter is briefly discussed. In Chapter 2, methodology and experimental design is 
discussed. The results for the impact of Nrf2 activation on BBR-induced mouse and 
human Bsep/BSEP and the impact of TLR4 inhibition on mouse Bsep are determined in 
Chapter 3 and discussed in Chapter 4. In Chapter 5, the significance and overview of my 
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dissertation are summarized. In addition, the potential future directions of my dissertation 
are identified and discussed. 
2.  Traditional Herbal Medicines 
        Traditional herbal medicines are widely used in approximately 80 percent of 
developing countries because of their relatively less toxicity and cheap price (Chung et 
al., 2012; Quartey et al., 2012; Tillhon et al., 2012).  
        Traditional herbal medicine generally consists of multiple active components, which 
work together to generate their therapeutic-effectiveness (Zhu and Woerdenbag, 1995). 
Recently, herbal medicine attracts more attention, especially its characteristic active 
components. For instance, berberine (BBR), a very old herbal medicine extracted from 
goldenseal and Hunaglian, has been extensively investigated because of its promising 
therapeutic potentials, including its anti-oxidative, anti-inflammatory, and anti-diabetic 
effects (Vickers et al., 2001; Tillhon et al., 2012). In addition, herbal medicine is very 
popular in the U.S. market, where several billions were spent on related products 
annually (Vickers et al., 2001).    
        However, some drawbacks restrict the therapeutic applications of herbal medicine. 
For instance, herbal medicine normally contains a mixture of different substances. Thus, 
it is difficult to identify and purify the exact active component (Bandaranayake, 2006). In 
addition, exploring the mechanism of action of herbal medicines is also challenging 
because the synergistic or antagonistic interaction among different components 
(Bandaranayake, 2006). Moreover, herbal medicine generally contains extremely low 
concentrations of active components, leading to low clinical efficiency (Firenzuoli and 
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Gori, 2007). Furthermore, few data are available for toxicological profiles of herbal 
medicine (Bandaranayake, 2006). 
        With the rapid development and emergency of advanced separation methodology, 
especially HPLC-MS/MS, increased number of active components of herbal medicine 
have been separated and identified (Yang et al., 2009). In addition, more elaborated 
animal studies have been conducted to investigate the mechanisms of action and the 
recommended dose of herbal medicine (Firenzuoli and Gori, 2007; Yi et al., 2013). All of 
above advancements promote the applications of traditional herbal medicine in disease 
diagnosis, prevention and therapy. 
        In my dissertation, I report that BBR, a major active component in several herbal 
medicines, such as goldenseal, Oregon grape and barberry, can induce expression and 
transport function of Bsep, and thus can promote bile flow  and relive endotoxemia-
induced cholestasis.  
3. Berberine (BBR) 
        Berberine (BBR), a cationic plant alkaloid, was originally isolated from Xanthoxylon 
cava by Cheballier and Pelletan in 1826 (Hahn and Ciak,1975). BBR can also be 
extracted from root, stem, bark, fruit and rhizome of other herbal medicine, such as 
Hydrastic canadenis (goldenseal) and Berberis vulgaris (barberry). In general, BBR is 
the major active component of above mentioned herbal medicine (Hahn and Ciak,1975; 
Harmon, 1990; Ivanovska and Philipov, 1996).  
        BBR has yellow fluorescence color and has been applied as a common fiber reactive 
dye in the textile industry and a special cell staining dye in the laboratory (Saxena and 
Raja, 2014; Weiß and Brandl, 2013). Herbal medicine containing BBR is extensively 
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used in India (Berberis aristata Linn), China (Huang Lian or Copis chinesis) and North 
America (Hydrastis canadensis) as the dietary supplement and folk remedies (Hahn and 
Ciak,1975; “Huang Lian”, 1986; McKenna and Plotnikoff 2005; Komal et al., 2011; 
Upton, 2011).  
        BBR shows broad pharmaceutical applications. Traditionally, BBR is used as an 
antibiotic (Hahn and Ciak,1975; Tillhon et al., 2012). It has been thought that its 
isoquinoline nucleus with quaternary nitrogen and methylenedioxy structure on C-2 and 
C-3 is essential for its anti-microbial property (Fig. 1.3) (Qing et al., 2017). In addition, 
positive charge of BBR can facilitate the interaction to negatively charged biological 
molecules, including bacteria DNA and RNA, and thus can inhibit bacteria growth 
(Davidson et al., 1977; Creasey, 1979; Bhadra et al., 2010). Furthermore, BBR has also 
been used to treat infections caused by fungi and protozoan (Amin et al., 1969; Basha et 
al., 2002).   
 
Figure 1.3 Chemical structure of berberine (BBR) 
Isoquinoline nucleus and methylenedioxy structure of BBR as highlighted by red and 





        Recently, BBR also shows potential to treat inflammatory diseases, type II diabetes 
and cancers. BBR suppresses inflammation most likely through blocking Toll-like 
receptor (TLR) 4-NF-кB inflammatory pathway, as well as inhibiting the synthesis of 
pro-inflammatory cytokines (Remppis, et al., 2010; Lou et al., 2011). BBR also 
suppresses the binding efficiency of lipopolysaccharides (LPS) to TLR4 (Kim et al, 
2004; Chu et al., 2014). In addition, BBR scavenges oxidative stress and modulates 
inflammation via activation of Nrf2 signaling, which play important anti-oxidative and 
anti-inflammatory roles (Mo et al., 2014). The mechanisms by which BBR activates Nrf2 
include the activation of PI3K/Akt-Nrf2 signaling and/or by following up-regulation of 
the expression of one LncRNA, MARK052686 (Hsu et al., 2012; Chen et al., 2012; Chen 
et al., 2014; Yuan et al., 2015). Next, BBR has been applied to treat type II diabetes 
because it increases glucose metabolism and insulin sensitivity via AMPK activation 
(Creasey, 1979; Yin et al., 2008; Brusq et al., 2006; Lee et al., 2006). BBR can also 
relieve diabetes-related complications, such as diabetic cardiovascular complications 
through preventing oxidative stress and reducing nitric oxide or cholesterol synthesis 
(Yin et al., 2012). Moreover, BBR is a putative chemotherapeutic agent by inhibiting 
DNA topoisomerases, p53-depedent cell growth, Akt signaling and cell division 
progression (Kobayashi et al., 1995; Serafim et al., 2008; Choi et al., 2009; Liu et al., 
2011; James et al, 2011; Kuo et al., 2012).  
        More and more evidence indicates that BBR has hepatoprotective effects by 
preventing the progression of hepatocellular carcinomas, non-alcoholic fatty liver 
(NAFLD), cholestasis, liver fibrosis, and drug-induced liver injury (DILI) (Wei and 
Gilani, 2000; Zhang et al., 2008; Sun et al., 2009, 2017; Liu et al., 2013). BBR promotes 
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autophagic cell death and mitochondrial apoptosis in hepatocellular carcinoma cells 
(Wang et al., 2010).  The mechanisms by which BBR ameliorates liver diseases involve 
anti-oxidative and anti-inflammatory effects, as well as improving lipid profile (Mo et al., 
2014; Fan et al., 2015; Wei, et al., 2016). For instance, BBR prevents chemical-induced 
hepatotoxicity and attenuates the progression of NAFLD in rats through Nrf2 activation 
(Deng et al., 2019). Similar to animal study, BBR attenuates the progression of NAFLD 
in patients, indicated by down-regulation of serum triglycerides, low-density lipoprotein 
(LDL), alanine aminotransferase (ALT) and HemoglobinA1C (HbA1C) (Yan et al., 
2015). In addition, goldenseal, in which BBR is the major active component, promotes 
bile flow (Newall, et al., 1996; Liu et al., 2013; Guo et al., 2016). We and others already 
reported that BBR induces the expression of Ntcp and Bsep, two bile acid transporters in 
mouse livers (Guo et al., 2016; Bu et al., 2017). 
        In addition to pharmaceutical effectiveness and safety, the pharmacokinetics of BBR 
has been well-documented. For example, oral administration of BBR shows extremely 
low bioavailability, which is less than 1% and 5% in human and rat, respectively (Chen et 
al., 2011; Liu et al., 2010; Liu et al., 2016). The low bioavailability of BBR is due to 
poor absorption, intestinal first-pass elimination and/or transporter-mediated efflux (Chen 
et al., 2011; Liu et al., 2010; Liu et al., 2016). After absorption, BBR primarily 
distributes to liver and can also be detected in kidney, muscle, lung, brain and heart in 
small amounts (Tan et al., 2013). In the liver, BBR is uptaken and effluxed by organic 
cation transporter (Oct)-1 and multidrug-resistance protein (MDR)1, respectively (Nies et 
al, 2008). BBR can be metabolized into four metabolites, including berberrubine (M1), 
thalifendine (M2), demethyleneberberine (M3) and jatrorrhizine (M4) by cytochrome 
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p450 (CYP) enzymes, including CYP1A2, CYP2D6 and CYP3A4 (Tsai and Tsai, et al., 
2002; Nies et al., 2008; Li et al., 2011; Tan et al., 2013). Finally, BBR is primarily 
eliminated through the urinary system (Chen and Chang, 1995; Tsai and Tsai, 2004). The 
half-life of BBR in rat serum and liver is 12.5±1.6 and 29.4±5.7 minutes, respectively 
(Tsai and Tsai, 2002). As a result, the effective doses of BBR in rodents are relatively 
higher because of poor absorption and short half-life. 
        Toxicological profile of BBR has also been reported. Oral LD50 of BBR is 1,000 
mg/kg in rats and 329 mg/kg in mice (Haginiwa et al.,1962; Kheir et al., 2010; Yi, et al., 
2013). To estimate the safe dose, mice were orally administrated with high doses of BBR 
for 6 hours. The limit of safety dose of BBR is 20.8 g/kg, which did not produce apparent 
mouse mortality (Kheir et al., 2010). There is no clear LD50 value or dose-response 
relationship of BBR toxicity in humans (Mills et al., 2004; Kheir et al., 2010). According 
to the safety dose in mice, the predicted safety dose of BBR in patients is about 2.97 g/kg, 
approximate 1 x 103 times higher than the clinical dose (Kheir et al., 2010). In general, 
BBR has been clinically used from 100 to 1,000 mg/kg/day without producing apparent 
toxicities (Vuddanda et al., 2010; Yin et al., 2008).   
        However, it has been reported that extremely high doses or chronic treatment of 
BBR could induce side effects and toxicities. For example, BBR can induce 
cardiotoxicity in dogs and immune toxicity in mice (Affuso et al., 2010; Mahmoudi et al., 
2016). In addition, BBR may induce jaundice in pregnant women and kernicterus in the 
neonates by replacing bilirubin from its binding protein in rat serum and thus, resulting in 
an increase of serum level of bilirubin (Chan, 1993). Moreover, chronic treatment of 
BBR can induce gastrointestinal side effects, such as diarrhea and constipation in patients 
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(Kowalewski et al., 1975; Bateman et al., 1998; Imanshahidi and Hosseinzadeh, 2008; 
Affuso et al., 2010)  
4. The Major Bile Acid Transporters in the Liver 
        Bile acid transporters are located at both sinusoidal and canalicular membranes of 
hepatocytes, which transport either unconjugated or conjugated bile acids, or both 
(Roberts et al., 2002; Klaassen and Aleksunes, 2010).  
        The primary function of liver bile acid transporters is to help to maintain bile acid 
homeostasis (Klaassen and Aleksunes, 2010). As shown in Figure 1.4, Na+-taurocholate 
cotransporting polypeptide (Ntcp) is the major liver bile acids uptake transporter. Bile 
salt export pump (Bsep) is the major liver bile acids efflux transporter (Roberts et al., 
2002). Both Ntcp and Bsep can control bile flow in the liver. In addition, some other 
transporters can also contribute to hepatic transport of bile acids. For example, organic 
anion transporting polypeptides (Oatps) facilitate bile acids uptake. Multidrug resistance-
associated proteins (Mrps) 2 and 3 are responsible for hepatic efflux of bile acids 
(Roberts et al., 2002).  
        Disruption of bile flow or dysfunction of bile acid transporters often leads to 
cholestasis and even liver fibrosis and ultimately cirrhosis (Trauner et al., 1998; Roberts 
et al., 2002; Byrne et al., 2002; Klaassen and Aleksunes, 2010;). For example, 
suppression or genetic knockout of Ntcp causes extrahepatic cholestasis in rats (Gartung 
et al., 1996). Mutations of BSEP gene cause type 2 progressive familial intrahepatic 
cholestasis (PFIC2) in patients (Paulusma et al., 1997; Strautnieks et al., 1998; Anwer, 
2004). In addition, patients with cholestatic liver injury often show disrupted or reduced 
9 
 
expression of hepatic bile acid transporters, including NTCP, MRPs and BSEP (Zollner 
et al., 2001; Anwer, 2004).  
 
Figure 1.4 Major bile acid transporters in the hepatocyte 
Ntcp and Oatp are responsible for hepatic uptake of bile acids whereas Bsep, Mrp2 and 
Mrp3 are responsible for cellular efflux of bile acids.  
5. Bile Salt Export Pump (Bsep) 
        Bile salt export pump (Bsep), also named ATP-binding cassette (ABC) transporter 
family B member 11 (ABCB11), is predominantly expressed in the canalicular membrane 
of hepatocytes (Török et al. 1999; Meier and Stieger, 2002). In addition, Bsep is 
minimally detected in other tissues (Török et al. 1999). 
        Bsep has 12 membrane-spanning helices, which are functionally grouped into two 
transmembrane domains (Gerloff et al. 1998). Bsep utilizes the energy from ATP 
hydrolysis to facilitate the efflux of its substrates against a concentration gradient (Meier 
and Stieger, 2002). Bsep transports primarily monovalent bile acids, including taurine 
and glycine conjugated bile acids, and some secondary bile acids, such as deoxycholic 




        The regulation of Bsep expression has been extensively investigated. It is well-
established that Bsep can be up-regulated following FXR activation, a master regulator 
that can sense the alteration of bile acid homeostasis (Parks et al., 1999; 
Ananthanarayanan et al., 2001; Gerloff et al., 2002). FXR signaling can be activated by 
bile acids, such as chenodeoxycholic acid (CDCA) (Makishima et al., 1999; Parks et al., 
1999). Activated FXR forms heterodimer with retinoid X receptor (RXR) alpha, and then  
binds to Inverted repeat-1 (IR-1) response elements in the promoter of its target genes to 
induce or suppress their expression (Makishima et al., 1999; Parks et al., 1999). In 
addition, Nrf2 signaling can up-regulate human BSEP expression in cultured human 
hepatoma cells (Weerachayaphorn et al., 2009). Nrf2 activation is also essential for Bsep 
expression under ischemia condition in rat liver (Kim et al., 2019). However, Nrf2 
activation appears not to induce mouse Bsep expression (Klaassen and Reisman, 2010).  
        Bsep expression can be down-regulated by estrogens (Crocenzi et al., 2003). For 
instance, estradiol-17β-D-glucuronide (E217G) inhibits Bsep transport function in rat 
liver (Crocenzi et al., 2003). In addition, lipopolysaccharides (LPS), the endotoxins 
extracted from outer membrane of Gram-negative bacteria can activate Toll-like receptor 
(TLR) 4 and then inhibit Bsep expression through NF-кB, the downstream inflammatory 
pathway (Adachi et al., 1998; Jiang et al., 2000; Shimazu et al., 1999; Sherry and 
Cerami, 1988; Raetz and Whitfield, 2002; Zollner et al., 2001; Hartmann et al., 2002). 
Furthermore, many drugs, like bosentan can inhibit Bsep efflux function in both in vivo 
and in vitro studies (Fattinger, et al., 2001).  
        Genetic mutations or dysfunction of Bsep often lead to bile acid accumulation and 
consequently cholestasis in patients (Anwer, 2004). Mechanistically, genetic mutations of 
11 
 
Bsep often lead to disruption of mRNA expression stability, alterations of BSEP 
targeting, and even shorter half-life of Bsep expression and turnover time in the 
membrane (Trauner and Boyer, 2003; Kullak-Ublick et al., 2004; Anwer, 2004). 
Therefore, mutations of Bsep gene cause defective bile secretion and severe cholestasis in 
the children, such as in the patients with progressive familial intrahepatic cholestasis 
(PFIC) 2 (Strautnieks, et al., 1998; Jansen et al., 1999). In addition, drug-induced 
cholestasis is often accompanied by reduced Bsep expression (Byrne et al., 2002). For 
example, cyclosporin and rifampicin, two validated competitive Bsep inhibitors, cause 
drug-induced liver injury (DILI) in patients (Byrne et al., 2002). Therefore, reversal of 
decreased Bsep expression can help to attenuate the progression of cholestasis.  
6. Aims  
        We propose that the effects of BBR to increase bile flow is partly mediated by up-
regulation of expression of major hepatic bile acid transporters, including Ntcp and Bsep. 
We have previously reported that BBR induced Ntcp expression via inhibition of Jak2-
Stat5 signaling (Bu, et al., 2017). The study objective of my dissertation focuses on 
characterization of regulation of Bsep expression by BBR. Specifically, I determined 
whether BBR induces Bsep expression and its transport function. In addition, the roles of 
Nrf2 and TLR4 signaling in BBR-induced Bsep/BSEP expression have been investigated. 
Specifically, in the first hypothesis, I determined the impact of Nrf2 activation on 
Bsep/BSEP induction by BRR. In the second hypothesis, I proposed that BBR induced 





CHAPTER 2 METHOLOGY 
1. Chemicals and Reagents 
        Berberine chloride was purchased from Alfa Aesar (cat. # AAJ6231106; Tewksbury, 
MA). Tak242 was purchased from Millipore (cat. # 50-833-600001; Burlington, MA). 
Lipopolysaccharides (LPS) was purchased from InvivoGen (cat. # NC0202558; San 
Diego, CA). Analysis kits of serum alanine aminotransferase (ALT) (cat. # A7526-150) 
and aspartate aminotransferase (AST) (cat. # A7561-150) were purchased from Pointe 
Scientific, Inc. (Ann Arbor, MI). Analysis kits of glucose (cat. # TR15221), triglycerides 
(cat. # TR22421) and cholesterol (cat. # TR13421), mem-PER Plus membrane protein 
extraction kit (cat. # 89842), NE-PER Nuclear and cytoplasmic extraction reagent kit 
(cat. # 78833), and Lipofectamine 2000 (cat. # 11668027) were purchased from Thermo 
Fisher Scientific Inc. (Waltham, MA). Chemiluminescent HRP Substrate (cat. # 
WBKLS0100) for Western blotting was purchased from Millipore (Billerica, MA). 
Zymoclean Gel DNA Recovery kit (cat. # D4001), Zymo Plasmid Miniprep kit (cat. # 
D4036) and  DNA Clean & Concentrator kit (cat. # D4013) were purchased from Zymo 
Research Corporation (Irvine, CA). All other reagents and chemicals, unless specifically 
indicated, were purchased from Thermo Fisher Scientific Inc. (Waltham, Massachusetts).  
2. Animal and Treatment 
        Approximately 8 weeks of age of male C57BL/6 wild-type mice (cat. # 000664), 
TLR4-mutated mice, C3H/HeJ (cat.  # 00659) and corresponding wild-type mice, 
C3H/OuJ (cat. # 00635) were purchased from the Jackson Laboratory (Bar Harbor, 
Maine). Nrf2-null mice, originally engineered in the Laboratory of Dr. Jefferson Chan at 
the University of California (Irvine, CA), were bred in the animal center at St. John’s 
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University. All animals were maintained under a standard 12-hour light: dark cycle with 
free access to regular rodent chow and water ad libitum. To mimic the clinical use of 
BBR, oral administration is used in animal study. In the studies to test Hypothesis I, both 
wild-type and Nrf2-null mice were orally treated with BBR (30 or 100 mg/kg) once daily 
for 14 days (n=6/treatment). Control group received saline. In the studies of Hypothesis 
II, mice were randomly divided into four groups and treated with 1) BBR (100 mg/kg; 
p.o.) once daily for 7 days; 2) LPS (2 mg/kg; i.p.) for 12 hours; 3) BBR (100 mg/kg; p.o.) 
for 7 days following LPS (2 mg/kg; i.p.) for 12 hours. Control group received saline (p.o. 
or i.p.). According to previous reports, BBR or LPS doses used in this study will alter 
Bsep expression and will not produce apparent hepatotoxicity (Bu et al., 2017; Li et al., 
2107).    
        Mouse condition was monitored daily. Either BBR or LPS treatment did not alter the 
body weight and animal behavior. After treatment, mouse livers and serum were 
collected and stored at -80°C for future analysis. One portion of freshly collected mouse 
liver was processed for histology study. 
3. Histopathology 
        After LPS treatment with or without BBR pre-treatment, mouse livers were fixed in 
10% formalin and then processed for Hematoxylin and Eosin (H&E) staining.   
4. Serum chemical assay 
        The serum levels of ALT, glucose, triglycerides and cholesterol in wild-type 
C57/BL6 mice and serum levels of ALT and AST in wild-type C3H/OuJ mice were 
analyzed using commercially available kits according to their instructions. 
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5. Cell Culture 
        Mouse Hepa1c1c7 hepatoma cells (cat. # CRL-2026; ATCC®; Manassas, VA) were 
cultured in Corning® MEM (Minimum Essential Medium) Alpha Medium (cat. # 
MT15012CV; Corning, NY). Human SNU449 hepatoma cells (cat. # CRL-2234; 
ATCC®; Manassas, VA) were cultured in Gibco™ DMEM High Glucose medium (cat. # 
11-995-065; Waltham, MA). The cell culture medium was supplemented with 10% heat-
inactivated fetal bovine serum (Atlanta Biologicals; Norcross, GA). Cells were cultured 
at 37°C with 5% CO2 atmosphere. Both mouse and human hepatoma cells were treated 
by BBR as we previously described (Bu et al., 2017). Briefly, mouse Hepa1c1c7 or 
human SNU449 hepatoma cells were seeded into 6-well plates (3 x105/well) and treated 
with BBR (5, 10 or 30 µM), in triplicate (Zhai et al., 2008; Bu et al., 2017). Mouse 
Hepa1c1c7 cells were also treated with LPS (10 ng/mL) in the presence or absence of 
BBR (10 µM) or Tak242 (0.3 mM), in triplicate. Control group received fresh medium. 
After 24 and 48 hours treatment, cells were collected and processed for mRNA and 
protein analysis, respectively.  
6. Transfection of siRNA 
        The small interfering RNAs (siRNA) against mouse (cat. # L-003755-00-0005) or 
human Bsep/BSEP (cat. # L-04076655-00-0005), as well as nontargeting negative control 
siRNA (cat. #D0018101005) were purchased from DharmaconTM(Lafayette, CO). Mouse 
Hepa1c1c7 and human SNU449 hepatoma cells were transfected to test silence efficiency 
using Lipofectamine messengerMAXTM reagent per manufacturer’s instructions (cat. # 
LMRNA003; Life Technologies; Carlsbad, CA). The successful gene silence should 
knockdown more than 75% of mRNA expression of target gene. After BBR treatment (10 
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µM) for 24 hours, cells were then collected and performed quantitative RT-PCR for 
mRNA analysis.   
7. Quantitative Real time-PCR (qRT-PCR) assay  
        Total RNAs from mouse liver and cultured hepatoma cells were extracted using 
TRIzol™ RNA extraction reagent (cat. # 15596026; Life Technologies; Carlsbad, CA) 
per the manufacturer’s instructions. RNA integrity was assessed by electrophoresis on a 
denatured agarose gel containing 3-(N-morpholino) propanesulfonic acid (MOPS) and 
formaldehyde. RNA concentrations were spectrophotometrically quantified at 260nm. 
Then, total RNAs were reversely transcribed into cDNA using SuperScriptTM II reverse 
transcriptase (cat. # 18064014; Life Technologies; Carlsbad, CA). Quantitative RT-PCR 
was performed using SYBR™ Select Master Mix (cat. # 4472903; Life Technologies; 
Carlsbad, CA) in an AriaMx qRT-PCR system (Agilent Technologies; Santa Clara, CA). 
Data was calculated according to the comparative delta-delta CT method. The results 
were presented as relative fold of the control. Primers of mouse or human Bsep/BSEP, 
Nrf2/NRF2 and its target genes, as well as inflammation genes were listed in Table 2.1. 
All quantitative RT-PCR primers were designed using PubMed Primer-BLAST or 
Primer3 software (NIH) and synthesized by Integrated DNA Technologies (Coralville, 
IA) or Eurofins Genomics (Louisville, KY). 
8. Immunocytochemistry (ICC) Staining  
        Mouse Hepa1c1c7 and human SNU449 hepatoma cells were cultured in chamber 
slides (cat. # 12-565-7; Thermo Fisher Scientific Inc.; Waltham, MA) and treated with or 
without BBR (5 or 10 μM) for 48 hours. Fixation and blocking were performed as 
previously described (Bu et al., 2017). Then, cells were incubated with the antibody 
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(1:100) against mouse/human Bsep/BSEP protein (cat. # PAB4697; Abnova; Walnut, 
CA) or the antibody (1:100) against mouse/human Nrf2/NRF2 protein (cat. # 12721; Cell 
Signaling Technology; Danvers, MA) overnight at 4°C. Next day, chamber slides were 
incubated with 1:300 Pierce Goat Anti-Rabbit IgG (H+L) Biotin Conjugated secondary 
antibody (cat. # 31820; Thermo Fisher Scientific Inc.; Waltham, MA) for 4  hours at room 
temperature. Cells were then washed and incubated with 1:400 Pierce High Sensitivity 
Streptavidin-HRP (cat. # 21130; Thermo Fisher Scientific Inc.; Waltham, MA) or 
Alkaline phosphatase streptavidin (cat. # SA5100; Vector Laboratories Inc.; Burlingame, 
CA) for 1 hour at room temperature. After final wash, color development was achieved 
using BCIP/NBT Alkaline phosphatase substrate kit (cat. # SK5400) in Vector 
Laboratories Inc. (Burlingame, CA) according to the manufacturer’s instructions.  
9. Western Blotting  
        Membrane and nuclear proteins from mouse liver and hepatoma cells were extracted 
using the Mem-PER Plus membrane protein extraction kit and the NE-PER Nuclear and 
cytoplasmic extraction reagents kit, respectively. Protein concentrations were quantified 
at 280 nm using spectrophotometer. Protein samples (30 ng/lane) were mixed with SDS 
loading buffer and heated and separated by 12% or 15% SDS-PAGE gel. After electro-
transfer blotting, PVDF membranes were blocked for 2 hours in 1xTBS supplemented 
with 5% non-fat milk or 5% BSA. PVDF membranes were then incubated with the 
antibody (1:1,000) against mouse/human Bsep/BSEP protein (cat. # PAB4697; Abnova; 
Walnut, CA), the antibody (1:1,000) against mouse/human Nrf2/NRF2 protein (cat. # 
12721; Cell Signaling Technology; Danvers, MA) or the antibody (1:1,000) against 
mouse and human Bsep/BSEP (cat. # PAB4697; Abnova; Walnut, CA) or antibody 
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(1:1,000) against mouse and human p65-NF-кB (cat.  # D14E12; Cell Signaling 
Technology; Danvers, MA) in 2.5% BSA at room temperature for 1 hour, followed by 
overnight incubation at 4°C. PVDF membranes were then washed and incubated with 
Pierce Goat Anti-Rabbit IgG (H+L) Biotin Conjugated secondary antibody (1:5,000; 
Thermo Fisher Scientific Inc.; Waltham, MA) in 1XTBS supplemented with 2.5% non-
fat milk for 2 hours at room temperature. Last, the membranes were incubated with 
Pierce High Sensitivity Streptavidin-HRP (cat. # 21130; 1:5000; Thermo Fisher 
Scientific Inc.; Waltham, MA) in 1XTBS supplemented with 0.5% BSA for 30 minutes at 
room temperature. Beta-actin (cat. # MA5-15739; 1:2,000; Pierce biotechnology; 
Waltham, MA) and Histone-H3 (cat. # 4499; 1:1,000; Cell Signaling Technology; 
Danvers, MA) were used as loading controls for membrane and nuclear proteins, 
respectively. Immunoreactive protein bands were detected with Immobilon Western 
Chemiluminescent HRP Substrate (cat. # WBKL S00 50; EMD Millipore, Billerica, 
MA). 
10. Analysis of Efflux Transport Function of Bsep/BSEP 
        The Bsep transport function was analyzed as previously reported (Li et al., 2008). 
Specifically, mouse Hepa1c1c7 and human SNU449 hepatoma cells were treated with 
BBR (10 µM) and then harvested for 48 hours. Collected cells were washed with cold 
1×PBS twice. The cells were aliquoted (1x106 per tube) into a 1.5 mL tube and incubated 
with dichlorofluorescin diacetate (cat. # D292648; Sigma-Aldrich; St. Louis, MO), a 
selective Bsep substrate for 40 minutes at 4°C. After incubation, cells were washed by 
cold 1XPBS twice and re-suspended with 1X PBS and then transferred into a new 1.5 mL 
tube. All tubes were incubated with a speed of 300 rpm at 37°C for 1 hour. Then, both 
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supernatant and cell pellet following centrifugation were collected. Cells were then 
lysated using 10% SDS solution. Dichlorofluorescin diacetate fluorescence was measured 
in both supernatant and cell lysate using Tecan Microplate Readers (Männedorf, 
Switzerland) at excitation 485 nm and emission 530 nm . 
11. Cloning of Bsep/BSEP Gene Promoters of Different Lengths 
        BAC clones containing mouse Bsep (cat. # RP23-291P1) and human BSEP (cat. # 
RP11-527A7) genes were purchased from BACPAC resources (Children's Hospital 
Oakland; Oakland, CA). The 2.9-kb of mouse Bsep gene promoter or 3.6-kb of human 
BSEP gene promoter was cloned from BAC clones via PCR analysis, and then 
engineered into polycloning site of the pGL3-basic vector (cat. # E1751; Promega; 
Fitchburg, WI). For truncated promoter constructs, the locations and sequences of the 
forward primers, the shared reverse primer were listed in Table 2.2. The sequences of 
different lengths of Bsep/BSEP gene promoters that were inserted into pGL3 reporter 
construct were validated by DNA sequencing (Eurofins Genomics; Huntsville, AL).  
12. Transfection and Dual-Luciferase® Reporter Assay 
       Recombinant pGL3 reporter constructs were transfected into mouse Hepa1c1c7 or 
human SNU449 cells, using Lipofectamine 2000 transfection reagent (cat.  # 11668027; 
Life Technologies, Inc.; Carlsbad, CA) following the manufacturer's instructions. Briefly, 
the cells were seeded onto 96-well tissue culture plates 1 day prior to transfection. 
Plasmid DNA (180-200 ng) of the empty pGL3-basic vector (cat. # E1751; Promega, 
Fitchburg, WI) or Bsep/BSEP promoter-containing pGL3 reporter constructs, plus 10 ng 
of pRL Renilla luciferase reporter vector (cat. # E2261; Promega; Madison, Wisconsin) 
was mixed with Lipofectamine 2000 with 1:1 ratio and then dispensed to each well. After 
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24 hours of incubation, transfection medium was replaced with fresh mediums with or 
without BBR at indicated concentrations. Forty-eight hours later, the cells were lysed and 
processed for Dual-Luciferase® reporter assay per the manufacturer's instructions (cat. #  
E1910; Promega; Fitchburg, WI). 
13. Statistical Analysis 
        Data were expressed as mean ± standard error. The data between control and BBR-
treated group were analyzed by Student’s t-test. Comparisons between more than two 
treatment groups were analyzed by one-way analysis of variance (ANOVA) followed by 
Duncan’s post-hoc tests (Sigmaplot; Systat Software, Inc.; San Jose, CA). The statistical 















Table 2.1: qPCR primers for analysis of mRNA expression of mouse and human 18s 




Gene Accession No. Forward primer Reverse primer 




























































Table 2.2: Sequences of PCR cloning primers of mouse and human Bsep/BSEP 
promoter. 
  
Bsep/BSEP promoter Promoter 
region 
Forward primer sequence 
pGL3-Bsep-2928 -2,843 to +85 P1: 
AAGACTGACGCGTGTGAGCTCC
TCT 
pGL3-Bsep-2120 -2,035 to +85 P2: 
TGGACTTCACGCGTGGGTGAT  
Shared reverse primers (m) AGAGACTCGAGTGTGGAAAGTC
A 
pGL3-BSEP-3680 -3,602 to +78 P1: TTCTGCTAGCCTGGGTCTCT 
pGL3-BSEP-377 -299 to +78 P2:  
GCAACACGCGTTTTCCAAGAG 
pGL3-BSEP-178 -100 to +78 P3: TTCCAACGCGTGTTGACAC 
Shared reverse primers (H) CAACCTCGAGTTTCATCATTC 
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CHAPTER 3 RESULTS 
1. Regulation of Mouse and Human Bsep/BSEP by BBR via Nrf2 Activation 
1.1. BBR Decreased Serum Level of Cholesterol in Wild-type Mice 
        BBR did not increase serum level of ALT, a biomarker of liver injury in wild-type 
mice (Fig. 3.1A). BBR at 100 mg/kg tended to decrease serum levels of glucose (Fig. 














Figure 3.1 Effects of BBR on serum chemical levels in wild-type mice. 
Wild-type C57BL/6 mouse sera were collected after BBR treatment (0, 30 or 100 mg/kg; 
p.o.) once daily for 14 days (n=6/treatment). Mice serum were collected and processed 
for serum chemical analysis of ALT (A), glucose (B), triglycerides (C) and cholesterol 










1.2. BBR Increased Bsep mRNA and Protein Expression in Mouse Liver and 
Hepatoma Cells 
        BBR dose-dependently induced mRNA expression of Bsep in wild-type (Fig. 3.2A) 
but not in Nrf2-null mouse livers (Fig. 3.2B). In addition, BBR increased membrane 
protein expression of Bsep in both wild-type and Nrf2-null mouse livers (Fig. 3.3A and 
B).  
        BBR induced mRNA expression of Bsep/BSEP in both mouse Hepa1c1c7 (Fig. 
3.4A) and human SNU449 (Fig. 3.4B) hepatoma cells. BBR dose-dependently increased 
membrane Bsep/BSEP protein expression in both mouse Hepa1c1c7 (Fig. 3.5A) and 
human SNU449 (Fig. 3.5B) hepatoma cells. In addition, immunocytochemistry (ICC) 
staining showed that BBR increased relative numbers of Bsep/BSEP protein-positive 
cells, which further demonstrated that BBR increased mouse and human Bsep/BSEP 














Figure 3.2 Regulation of Bsep mRNA expression by BBR in wild-type and Nrf2-null 
mouse livers. 
Adult male C57BL/6 wild-type mice and age-matched male Nrf2-null mice were orally 
treated with BBR (0, 30 or 100 mg/kg) once daily for 14 days (n=6/treatment). Mouse 
livers were harvested 14 days later and processed for quantitative RT-PCR analysis of 
Bsep mRNA expression in wild-type (A) and Nrf2-null (B) mouse livers. Statistical 










Figure 3.3 Regulation of Bsep protein expression by BBR in wild-type and Nrf2-null 
mouse livers. 
Adult male C57BL/6 wild-type and age-matched male Nrf2-null mice were orally treated 
with BBR (0, 30 or 100 mg/kg) once daily for 14 days (n=6/treatment). Membrane 
proteins, extracted from wild-type (A) and Nrf2-null (B) mouse livers, were processed for 
analysis of Bsep protein expression by Western blotting. Statistical differences (p <0.05) 











Figure 3.4 Regulation of Bsep/BSEP mRNA expression by BBR in cultured mouse 
and human hepatoma cells.  
Quantitative RT-PCR was conducted to determine mRNA levels of Bsep/BSEP in 
cultured mouse Hepa1c1c7 (A) and human SNU449 (B) hepatoma cells following BBR 
treatment (0, 5, 10 or 30 µM) for 24 hours. Data are expressed as mean ± S.E., 
(n=3/treatment). Statistical differences (p <0.05) are indicated between BBR and control 












Figure 3.5 Regulation of Bsep/BSEP protein expression by BBR in cultured mouse 
and human hepatoma cells. 
Mouse Hepa1c1c7 and human SNU449 hepatoma cells, in triplicate, were treated with 
BBR (0, 5, or 10 µM) for 48 hours. Cytosolic and membrane proteins, extracted from 
mouse (A) and human (B) hepatoma cells were analyzed for Western blotting of 
Bsep/BSEP protein expression. Data are expressed as mean ± S.E., (n=3/treatment). 












Figure 3.6 Immunocytochemistry staining of Bsep/BSEP protein in BBR-treated 
mouse and human hepatoma cells. 
Immunocytochemistry staining of Bsep/BSEP protein in BBR treated mouse Hepa1c1c7 
(A, top panel) and human SNU449 (A, bottom panel) hepatoma cells. 200× 
magnification, (Scale bar: 100 μm). Counting of Bsep/BSEP positive cells in a total of 
1,000-1,500 cells (averaged on 20 random fields) per treatment in BBR-treated mouse (B, 
top panel) and human (B, bottom panel) hepatoma cells. Statistical differences (p <0.05) 









1.3. BBR Increased Cellular Efflux of Bsep Substrate in Hepatoma Cells  
        Bsep/BSEP efflux function was assessed by monitoring cellular efflux of 
dichlorofluorescin diacetate, a selective Bsep substrate, into the culture medium. As 
shown in Fig. 3.7, BBR treatment leads to an increase of dichlorofluorescin diacetate 
concentrations in culture medium of both mouse Hepa1c1c7 and human SNU449 
hepatoma cells. Accordingly, BBR treatment produces a decrease of dichlorofluorescin 
diacetate concentrations in the cell lysates of both mouse and human hepatoma cells (Fig. 










Figure 3.7 BBR enhances Bsep/BSEP efflux function in cultured mouse and human 
hepatoma cells.  
Mouse Hepa1c1c7 and human SNU449 hepatoma cells, in triplicate, were treated with 
BBR (10 µM) for 48 hours. Efflux of dichlorofluorescin diacetate, a selective Bsep 
substrate was measured in mouse (A) and human (B) hepatoma cells. All data are 
expressed as mean ± S.E., (n=3/treatment). Statistical differences (p <0.05) are indicated 









1.4. BBR Activates Nrf2 Signaling in Hepatoma Cells but not in Mouse Livers  
        BBR dose-dependently induced mRNA expression of Ho-1 and Nqo-1, two known 
Nrf2-target genes in wild-type (Fig. 3.8A) but not in Nrf2-null mouse livers (Fig. 3.8B). 
However, in wild-type mouse livers, BBR did not significantly increase nuclear Nrf2 
protein level (Fig. 3.9). 
        In addition, BBR induced mRNA expression of Ho-1/HO-1 and Nqo-1/NQO-1 in 
both mouse Hepa1c1c7 (Fig. 3.10A) and human SNU449 (Fig. 3.10B) hepatoma cells. 
BBR also increased nuclear levels of Nrf2/NRF2 proteins (Fig. 3.11A and B), as well as 
the relative number of Nrf2/NRF2 protein-positive cells (Fig. 3.12A and B) in mouse and 










Figure 3.8 Regulation of mRNA expression of Ho-1 and Nqo-1 by BBR in wild-type 
and Nrf2-null mouse livers. 
Adult male C57BL/6 wild-type and age-matched male Nrf2-null mice were orally treated 
with BBR (0, 30 or 100 mg/kg) once daily for 14 days (n=6/treatment). The mouse livers 
were collected 14 days later and then processed for quantitative RT-PCR analysis of 
mRNA expression of Ho-1 and Nqo-1 in wild-type (A) and Nrf2-null (B) mouse livers. 




Figure 3.9 Regulation of cytosolic and nuclear Nrf2 protein levels by BBR in mouse 
livers. 
Adult male C57BL/6 wild-type mice were orally treated with BBR (0, 30 or 100 mg/kg) 
once daily for 14 days (n=6/treatment). Cytosolic and nuclear proteins, extracted from 
wild-type mouse livers were processed for Western blotting of Nrf2 protein expression. 









Figure 3.10 Regulation of mRNA expression of Ho-1/HO-1 and Nqo-1/NQO-1 in 
cultured mouse and human hepatoma cells. 
Quantitative RT-PCR analysis of mRNA expression of Nrf2/NRF2-targte genes, Ho-
1/NO-1 and Nqo-1/NQO-1 in cultured mouse Hepa1c1c7 (A) and human SNU449 (B) 
hepatoma cells following BBR treatment (0, 5, 10 or 30 µM). All data are expressed as 
mean ± S.E., (n=3/treatment). Statistical differences (p <0.05) are indicated between BBR 













Figure 3.11 Regulation of nuclear Nrf2/NRF2 protein level in cultured mouse and 
human hepatoma cells.  
Mouse Hepa1c1c7 and human SNU449 hepatoma cells were treated with BBR (0, 5, or 
10 µM), in triplicate for 48 hours. Cytosolic and nuclear proteins, extracted from mouse 
(A) and human (B) hepatoma cells were analyzed for Western blotting of Nrf2/NRF2 
protein expression. All data are expressed as mean ± S.E., (n=3/treatment). Statistical 











Figure 3.12 Immunocytochemistry staining of Nrf2/NRF2 protein in BBR-treated 
mouse and human hepatoma cells. 
Immunocytochemistry staining of Nrf2/NRF2 protein in BBR treated mouse Hepa1c1c7 
(A, top panel) and human SNU449 (A, bottom panel) hepatoma cells. 200× 
magnification, (Scale bar: 100 μm). Counting of Nrf2/NRF2 positive cells with a total of 
1,000-1,500 cells (averaged on 20 random fields) in BBR or control treated mouse (B, 
top panel) and human (B, bottom panel) hepatoma cells. Statistical differences (p <0.05) 






1.5. The Impact of Nrf2/NRF2 mRNA Silencing on BBR-induced Mouse and 
Human Bsep/BSEP Expression 
        In mouse hepatoma cells, Nrf2 siRNA treatment reduced Nrf2 mRNA levels about 
75%, and largely repressed BBR-induced Bsep mRNA expression (Fig. 3.13). BBR still 
slightly increased Bsep mRNA expression after Nrf2 silence. 
        In human hepatoma cells, NRF2 siRNA treatment knocked down NRF2 mRNA 
levels more than 86%, and almost completely abolished BBR-induced BSEP mRNA 









Figure 3.13 Nrf2 silence attenuated BBR-induced mouse Bsep expression. 
Mouse Hepa1c1c7 hepatoma cells were treated with BBR (10 µM), in triplicate in the 
presence or absence of Nrf2 siRNA for 24 hours. Quantitative RT-PCR analysis for 
mRNA expression of Nrf2 (Left panel) and Bsep (Right panel) was determined in mouse 
hepatoma cells. All data are expressed as mean ± S.E., (n=3/treatment). Statistical 
differences (p <0.05) are indicated between BBR and control group (*), or between with 




Figure 3.14 NRF2 silence abolished BBR-induced human BSEP expression.  
Human SNU449 hepatoma cells were treated with BBR (10 µM), in triplicated in the 
presence or absence of NRF2 siRNA for 24 hours. Quantitative RT-PCR analysis for 
mRNA expression of NRF2 (Left panel) and BSEP (Right panel) was next determined in 
human hepatoma cells. All data are expressed as mean ± S.E., (n=3/treatment). Statistical 
differences (p <0.05) are indicated between BBR and control group (*), or between with 
NRF2 siRNA treatment and without NRF2 siRNA treatment (#). 





1.6. Removal of Putative NRF2 ARE from Bsep/BSEP Promoter Results in 
Altered Promoter Activity      
        To determine the role of Nrf2 signaling in BBR-induced mouse and human 
Bsep/BSEP expression, we engineered a series of recombinant pGL3 reporter constructs 
containing different lengths of Bsep/BSEP promoters, as indicated in Figs. 3.15, 3.16 and 
3.17.  Luciferase activities that were driven by the 2.9-kb mouse and 3.7-kb human 
Bsep/BSEP gene promoters, were both concentration-dependently induced by BBR (Fig. 
3.15A and B).  
        In mouse hepatoma cells, luciferase reporter activity driven by 2.9-kb mouse Bsep 
promoter (ranged from -2,843 to +85bp) with a putative antioxidative response element 
(ARE) located at -2,760 bp upstream of transcriptional start site (Fig. 3.16) is induced by 
BBR treatment in a concentration-dependent manner. In addition, we also engineered a 
truncated Bsep promoter that does not contain putative ARE (ranged from -2035 to 
+85bp) into pGL3 basic vector (Fig. 3.16). To our surprise, the luciferase activity of the 
truncated mouse Bsep promoter-driven pGL3 construct was even increased more by BBR 
treatment as compared to 2.9-kb mouse Bsep promoter-driven pGL3 construct, indicating 
that Nrf2 activation may suppress mouse Bsep expression.  
        In human hepatoma cells, the 3.7-kb human BSEP promoter (ranged from -3,602 to 
+78bp), which contains one putative ARE located at -100 to +78bp relative to 
transcriptional start site can be activated by BBR treatment (Fig. 3.17). We also 
engineered a shorter fragment of BSEP promoter with one putative ARE, as depicted in 
Fig. 2.16 to determine whether enhancer regulated human BSEP expression. The result 
showed that BBR still increased luciferase activity in these constructs with one putative 
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ARE. In contrast, the truncated human BSEP promoter that does not contain the putative 
ARE, as depicted in Fig. 3.17, cannot be activated by BBR treatment. This indicates that 

















Figure 3.15 The impact of BBR on the activation of mouse and human Bsep/BSEP 
promoter determined by dual luciferase reporter assays in cultured mouse and 
human hepatoma cells. 
Bsep/BSEP gene promoter-driven recombinant pGL3 reporter constructs were transfected 
into hepatoma cells. The regulation of luciferase activity, which is driven mouse or 
human Bsep/BSEP gene promoter was determined in mouse Hepa1c1c7 (A) and human 
SNU449 (B) hepatoma cells following BBR treatment (0, 10, or 30µM) for 48 hours. All 
data are expressed as mean ± S.E., (n=3/treatment). Statistical differences (p <0.05) are 







Figure 3.16 The impact of removal of putative ARE that is located in the Bsep gene 
promoter on the BBR-activated mouse Bsep promoter. 
After deletion of putative ARE (-2,770 to -2,760) in the mouse Bsep promoter, BBR 
treatment (0, 5, or 10 µM) activated Bsep gene promoter even stronger in mouse 
hepatoma cells. All data are expressed as mean ± S.E., (n=3/treatment). Statistical 
differences (p <0.05) are indicated between BBR and control group (*), or between m-











Fig. 3.17 The impact of removal of putative ARE that is located in human BSEP 
gene promoter on the BBR-activated human BSEP promoter. 
Compared to 3.7-kb human BSEP promoter (-3,602 to +78) and truncated 0.4-kb human 
BSEP promoter (-299 to +78), deletion of putative ARE (-113 to -103) on human BSEP 
promoter led to no more activation of human BSEP gene promoter by any concentration 
of BBR treatment (0, 5, or 10 µM) in human hepatoma cells. All data are expressed as 
mean ± S.E., (n=3/treatment). Statistical differences (p <0.05) are indicated between BBR 






2. Regulation of Mouse Bsep by BBR via TLR4 Inactivation 
2.1. LPS Did Not Increase Serum Levels of Liver Injury Biomarkers in Wild-
type C3H/OuJ Mice 
        LPS at 2 mg/kg did not increase serum levels of ALT or AST in wild-type C3H/OuJ 
mice (Fig. 3.18A and B). In addition, BBR or BBR pre-treatment did not alter serum 















Figure 3.18 LPS did not increase serum levels of ALT or AST in wild-type mice 
Wild-type C3H/OuJ mouse sera were collected after BBR treatment (100 mg/kg; p.o.) 
once daily for 7 days and/or LPS treatment (2 mg/kg; i.p.) once on day 7 for 12 hours 
(n=6/treatment). Serum levels of ALT (A) and AST (B) in mice were measured (n= 













2.2. BBR Relieved LPS-Induced Liver Injury and Inflammation in Wild-type 
C3H/OuJ but not in TLR4-mutated C3H/HeJ Mouse Livers 
        BBR did not induce liver injury in wild-type C3H/OuJ mouse livers (Figs. 3.19). 
LPS induced apparent liver injury and inflammation, evidenced by cell swelling, diluted 
and congested sinusoidal space, and increased number of infiltrated immune cells (Figs. 
3.19). Pre-treatment of BBR attenuated LPS-induced liver injury and inflammation, as 
indicated by recovered normal cell morphology and decreased number of infiltrated 
immune cells (Fig. 3.19). In contrast, in TL4-mutated C3H/HeJ mouse livers, LPS did not 











Figure 3.19 LPS-induced liver injury was attenuated by BBR in wild-type C3H/OuJ 
mouse livers. 
Wild-type C3H/OuJ mouse livers were collected after BBR treatment (100 mg/kg; p.o.) 
once daily for 7 days and/or LPS treatment (2 mg/kg; i.p.) once on day 7 for 12 hours and 
processed for histology analysis (n=6/treatment). H & E staining of mouse livers 
following BBR and/or LPS treatment. 200× magnification, (Scale bar: 200 μm). Green 
cycle: cell damage; Black arrowhead, diluted sinusoidal space; Yellow shorter arrow: 












Figure 3.20 LPS did not induce liver injury in TLR4-mutated C3H/HeJ mouse 
livers. 
TLR4-mutated C3H/HeJ mouse livers were collected after BBR treatment (100 mg/kg; 
p.o.) once daily for 7 days and/or LPS treatment (2 mg/kg; i.p.) once on day 7 for 12 
hours and processed for histology analysis (n=6/treatment). H & E staining of mouse 



















2.3. BBR Reversed LPS-Inhibited Bsep Expression Through Suppressing 
TLR4-NF-кB Signaling 
        In wild-type C3H/OuJ mouse livers, BBR induced Bsep mRNA expression but LPS 
decreased Bsep mRNA expression (Fig. 3.21A). Pre-treatment of BBR reversed LPS-
inhibited Bsep expression. In contrast, in TLR4-mutated C3H/HeJ mouse livers, LPS did 
not decrease Bsep mRNA expression (Fig. 3.21B). In addition, pre-treatment of BBR did 
not alter Bsep expression as compared to LPS alone.  
        BBR also increased membrane Bsep protein expression but LPS decreased 
membrane Bsep protein expression in wild-type C3H/OuJ mouse livers (Fig. 3.22A). Pre-
treatment of BBR reversed LPS-inhibited Bsep protein expression (Fig. 3.22A). In 
contrast, in TLR4-mutated C3H/HeJ mouse livers, LPS did not reduce Bsep protein 
expression (Fig. 3.22B). In addition, pre-treatment of BBR also tended to increase Bsep 
protein level in TLR4-mutated C3H/HeJ mouse livers (Fig. 3.22B). 
        We next determined the impact of BBR on NF-кB, the downstream molecules of 
TLR4 signaling. In wild-type C3H/OuJ mouse livers, LPS increased nuclear level of p65-
NF-кB protein (Fig. 3.23A). Pre-treatment of BBR inhibited the nuclear translocation of 
p65-NF-кB protein. In contrast, in TLR4-mutated C3H/HeJ mouse livers, LPS did not 
increase nuclear level of p65-NF-кB protein (Fig. 3.23B).   
        In addition, LPS induced NF-кB downstream cytokine genes, such as TNF-α, IL-1β 
and IL-6 in wild-type C3H/OuJ mouse livers (Figs. 3.24A, B and C). Pre-treatment of 
BBR reversed LPS-induced mRNA expression of cytokine genes. In contrast, LPS did 
not induce mRNA expression of TNF-α in TLR4-mutated C3H/HeJ mouse livers (Fig. 
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3.24A). Compared to wild-type mouse livers, TLR4-mutated C3H/HeJ mouse livers also 




















Figure 3.21 LPS-inhibited Bsep mRNA expression was reversed by BBR pre-
treatment in mouse livers. 
Wild-type C3H/OuJ and TLR4-mutated C3H/HeJ mice were treated with BBR (100 
mg/kg; p.o.) once daily for 7 days or/and a single dose of LPS (2 mg/kg; i.p.) on day 7 for 
12 hours (n=6/treatment). Quantitative RT-PCR analysis of mRNA expression of Bsep in 
wild-type (Fig. 3.21A) and TLR4-mutated (Fig. 3.21B) mouse livers. Statistical 







Figure 3.22 LPS-inhibited Bsep protein expression was reversed by BBR pre-
treatment in mouse livers. 
Wild-type C3H/OuJ and TLR4-mutated C3H/HeJ mice were treated with BBR (100 
mg/kg; p.o.) once daily for 7 days or/and a single dose of LPS (2 mg/kg; i.p.) on day 7 for 
12 hours. Membrane proteins extracted from wile-type (A) and TLR4-mutated (B) mouse 
livers were analyzed for Western blotting of Bsep protein expression. Statistical 












Figure 3.23 LPS-induced p65-NF-kB protein expression was attenuated by BBR 
pre-treatment in mouse livers. 
Wild-type C3H/OuJ and TLR4-mutated C3H/HeJ mice were treated with BBR (100 
mg/kg; p.o.) once daily for 7 days or/and a single dose of LPS (2 mg/kg; i.p.) on day 7 for 
12 hours (n=6/treatment). Nuclear proteins extracted from wile-type (A) and TLR4-
mutated (B) mouse livers were analyzed for Western blotting of p65-NF-kB protein 














Figure 3.24 LPS-induced cytokine mRNA expression was attenuated by BBR pre-
treatment in mouse livers. 
Wild-type C3H/OuJ and TLR4-mutated C3H/HeJ mice were treated with BBR (100 
mg/kg; p.o.) once daily for 7 days or/and a single dose of LPS (2 mg/kg; i.p.) on day 7 for 
12 hours (n=6/treatment). Quantitative RT-PCR analysis of mRNA expression of TNF-α, 
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IL-1β and IL-6 in wild-type and TLR4-mutated mouse livers (Figs. 3.24A, B and C). 























2.4.  BBR Reversed TLR4-Inhibited Bsep mRNA Expression in Mouse 
Hepatoma Cells 
        As shown in Fig. 3.25A, LPS reduced Bsep mRNA expression in mouse hepatoma 
cells. Pre-treatment of BBR reversed LPS-decreased Bsep mRNA expression (Fig. 
3.25A). In addition, Tak242, the TLR4 inhibitor, also reversed LPS-suppressed Bsep 















Figure 3.25 LPS-repressed Bsep mRNA expression was reversed by pre-treated with 
BBR in cultured mouse hepatoma cells. 
Mouse Hepa1c1c7 hepatoma cells, in triplicate, were treated with LPS (10 ng/mL) in the 
presence or absence of BBR treatment (10 µM) or TLR4 inhibitor, TAK242 treatment 
(0.3mM) for 24 hours. Quantitative RT-PCR analysis of mRNA expression of Bsep in 
BBR (A) and TAK242 (B) treated mouse hepatoma cells. Data are expressed as 
mean ± S.E (n=3/treatment). Statistical differences (p <0.05) are indicated between 





CHAPTER 4 DISCUSSION 
        It has been previously reported that goldenseal, in which BBR is the major active 
component, promotes bile flow (Newall, et al., 1996). We recently also reported that 
BBR promotes bile flow maybe via induction of cytochrome p450 (Cyp) 7a1, Ntcp and 
Bsep, several bile acid-related genes in the liver, and that BBR induces Ntcp expression 
via inhibiting Jak2-Stat5 signaling (Bu et al., 2017). The studies proposed in my 
dissertation project characterized the underlying mechanisms by which BBR induces 
mouse and human Bsep/BSEP expression. Bsep expression is primarily induced by FXR 
signaling. However, the mechanisms other than FXR activation is responsible for BBR-
induced Bsep expression because BBR below 300 mg/kg did not activate FXR signaling 
(Guo et al., 2016). In addition, it is well-known that activation of FXR will down-
regulate Ntcp and Cyp7a1 expression. However, as mentioned above, BBR actually 
induced the expression of Ntcp and Cyp7a1. In my dissertation, I reported that BBR 
induced Bsep/BSEP expression and transport function in mouse liver, as well as in mouse 
and human hepatoma cells. In addition, BBR induced human BSEP expression through 
NRF2 activation and induced mouse Bsep expression most likely through TLR4 
inhibition. 
        First, similar as previously reported, BBR did not induce apparent liver injury, 
evidenced by no change in mouse behavior and body weight, as well as serum levels of 
ALT, a biomarker of liver injury (Fig. 3.1A). BBR also reduced serum levels of glucose 
and lipids in mice, indicating potential hepatoprotective roles (Yin et al., 2008; Zhao et 
al., 2019). It has been reported that BBR alone did not induce oxidative stress in both 
mouse liver and cultured hepatocytes (Dkhil et al., 2014; Liu et al., 2012). Pre-treatment 
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of BBR even inhibited tert-butyl hydroperoxide-induced ROS and lipid peroxidation in 
rat liver (Hwang et al., 2002). Thus, BBR is a potential Nrf2 activator but not a pro-
oxide. 
        In addition, BBR increased Bsep/BSEP mRNA and protein expression in mouse 
liver (Figs. 3.2 and 3.3), as well as in mouse and human hepatoma cells (Figs. 3.4, 3.5 
and 3.6). Consistent to Bsep/BSEP gene regulation, BBR also enhanced Bsep/BSEP 
efflux transport function, evidenced by increased cellular efflux of dihydrofluorescein 
diacetate, a selective Bsep substrate in both mouse and human hepatoma cells (Wang et 
al., 2003) (Fig. 3.7). 
        I next determined the impact of Nrf2 activation on Bsep/BSEP expression by BBR. 
Similar to previous reports, BBR activated Nrf2 signaling, evidenced by increased 
mRNA expression of Nrf2-target genes, including Ho-1/HO-1 and Nqo-1/NQO-1, in 
wild-type mouse livers (Fig. 3.8A) and mouse and human hepatoma cells (Fig. 3.10), but 
not in Nrf2-null mouse livers (Fig. 3.8B). To our surprise, BBR did not induce nuclear 
translocation of Nrf2 protein in mouse livers (Fig. 3.9), which was contradictory to 
previous reports (Deng et al., 2019; Mo et al., 2012; Hsu et al., 2012). This discrepancy 
between our and other results could be interpreted by species and model difference, as 
well as different time period of BRR treatment. In contrast, as shown in Fig. 3.11 and 
3.12, BBR induced nuclear translocation of Nrf2/NRF2 protein in both mouse and human 
hepatoma cells. This result was consistent to previous studies, BBR activated Nrf2 
signaling in cultured neuron and human hepatoma cells (Hsu et al., 2012 and 2013; Sun 
et al., 2017). The differences regarding Nrf2 activation by BBR between mouse liver and 
mouse hepatoma cells is most likely due to loss of hepatocyte morphology and polarity in 
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cultured hepatoma cells, which leads to reduced expression or even complete loss of drug 
metabolized enzymes and transporters (Bachmann et al., 2015). Consequently, without 
normal metabolism and efflux function, BBR can stay inside the hepatoma cells for 
longer time as compared in the liver. 
        Nrf2-null mouse model and siRNA knockdown were also applied to investigate the 
role of Nrf2/NRF2 activation in BBR-induced Bsep/BSEP expression. As shown in Fig. 
3.3B, BBR increased Bsep protein expression in the membrane of both wild-type and 
Nrf2-null mouse livers, indicating that BBR-induced Bsep expression is independent of 
Nrf2 activation in mouse liver. This was consistent to several reports, which documented 
that mouse Bsep was not a downstream target of Nrf2 signaling (Klaassen and Reisman, 
2010; Reisman et al.,2009; Cheng et al., 2007). In addition, a potential Nrf2 activator, 
ursodeoxycholic acid did not increase Bsep expression in mouse liver (Okada et al., 
2008). Next, we used Nrf2/NRF2 siRNA to knockdown mRNA expression of Nrf2/NRF2 
in hepatoma cells. In Nrf2-silenced mouse hepatoma cells, BBR still slightly increased 
Bsep mRNA expression (Fig. 3.13). This indicated that Nrf2 may be not solely 
responsible for BBR to induce mouse Bsep expression. In contrast, in NRF2-silenced 
human hepatoma cells, BBR-induced BSEP induction was blocked completely, 
indicating the necessity of NRF2 activation for BBR-induced human BSEP expression 
(Fig. 3.14). 
        To further determine the role of putative Nrf2 response element(s) in the BBR-
induced Bsep/BSEP gene expression, luciferase reported assays were processed. 
Luciferase reported assays first showed that BBR activated mouse and human 
Bsep/BSEP promoter activity (Fig. 3.15). Then, a series of Bsep/BSEP gene promoters 
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with different lengths were cloned and then engineered cloned Bsep/BSEP gene 
promoters into pGL3-basic reporter construct as depicted in Figs. 3.16 and 3.17. In 
mouse hepatoma cells, BBR continued to increase the luciferase activity driven by mouse 
Bsep gene promoters in which putative Nrf2 binding site does not exist, indicating that 
Nrf2 activation was not required for BBR-induced mouse Bsep expression (Fig. 3.16). In 
contrast, in human hepatoma cells, BBR can no longer increase the luciferase activities 
that are driven by human BSEP gene promoters in which putative NRF2 binding site does 
not exist (Fig. 3.17). The difference between mouse and human hepatoma cells is due to 
species differences in the sequence of Bsep/BSEP gene promoter (Klaassen and Reisman, 
2010). 
        Because BBR-induced mouse Bsep expression appeared not to be due to Nrf2 
activation, we next determined whether other mechanisms are responsible for mouse 
Bsep induction by BBR. Several reports showed that BBR inhibited TLR4 activity and 
that TLR4-NF-kB inflammatory signaling repressed Bsep expression (Hsiang et al., 
2005; Enk et al., 2007; Chu et al., 2014). Therefore, we determined the impact of BBR-
repressed TLR4 signaling on mouse Bsep expression. 
        Consistent to previous reports, pre-treatment of BBR inhibited LPS-induce liver 
injury and inflammation in mouse liver (Chu et al., 2014; Lou et al., 2010). In wild-type 
mice, LPS did not increase serum levels of ALT and AST (Fig. 3.18) but induced 
apparent liver injury and inflammation in mouse liver (Fig. 3.19). LPS-induced liver 
damage can be characterized by megatocytosis and dilated sinusoidal space (Liu et al., 
2018; Fang et al., 2013; Greuter and Shah, 2016). LPS also stimulated acute 
inflammatory through activation of immune cells, such as macrophages/Kupffer cells and 
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neutrophils in mouse liver, which was evidenced by increased number of cell infiltration 
(Fig. 3.19) (Karlmark et al., 2008). In addition, LPS induced TLR4 downstream 
molecules, NF-кB protein and its target cytokine expression (Figs. 3.23A and 3.24) (Chu 
et al., 1999; Jiang et al., 2000). In contrast, pre-treatment of BBR attenuated LPS-
induced liver injury and inflammation in histology study (Fig. 3.19), and also modulated 
NF-кB signaling and its downstream gene expression (Figs. 3.23A and 3.24). The results 
were similar to previous reports, showing that BBR inhibited TLR4-mediated 
inflammation through inhibiting nuclear translocation of NF-кB protein and/or 
production of cytokines (Enk et al., 2007; Chu et al., 2014; Lou et al., 2010). 
        Next, we determined the role of TLR4 signaling in BBR-induced mouse Bsep 
expression. In mouse livers, LPS inhibited Bsep mRNA and protein expression (Figs.  
3.21 and 3.22A) (Hsiang et al., 2005; Enk et al., 2007). However, pre-treatment of BBR 
reversed LPS-decreased Bsep mRNA and protein expression (Figs. 3.21 and 3.22A). This 
indicated that the suppression of TLR4 by BBR can up-regulate mouse Bsep expression. 
To further investigate the role of TLR4 inhibition in mouse Bsep expression, we used 
TLR4-mutated C3H/HeJ mouse model. Since TLR4 is dysfunctional in C3H/HeJ mouse 
livers, LPS, as expected, did not induce liver injury and inflammation, and also did not 
inhibit Bsep expression (Figs. 3.20 and 3.23B and 3.24) (Paik et al., 2003). This indicated 
that TLR4 inactivation is a putative strategy to reverse inflammation mediated Bsep 
inhibition. Furthermore, BBR and TAK242, a known TLR4 inhibitor, both reversed LPS-
repressed Bsep expression in cultured mouse hepatoma cells (Fig. 3.25). Therefore, it is 




        Taken together, our results demonstrated that BBR increased mouse and human 
Bsep/BSEP expression. In addition, NRF2 activation contributes to BBR-induced human 






CHAPTER 5 SUMMARY AND CONCLUSIONS 
        With extensive investigation, more and more therapeutic effects of BBR have been 
revealed, including anti-inflammatory, anti-diabetic, and anti-cancer effects (Puthdee et 
al., 2017; Lee et al., 2006; Diaz et al., 2015; Doggrell, 2005). In addition, BBR has been 
recognized as a promising candidate to treat liver diseases, which is most likely due to its 
anti-oxidative and anti-inflammatory properties (Vuddanda et al., 2010). We and others 
also demonstrated that BBR can promote bile flow (Newall, et al., 1996; Bu et al., 2017).  
        As an essential approach for absorption of lipid-soluble vitamins and elimination of 
xenobiotic, bile acid homeostasis is tightly regulated by multiple nuclear receptors and 
transporters (Anwer, 2004). For example, we previously reported that BBR induced 
mouse and human Ntcp/NTCP expression through down-regulation of Jak2-Stat5 
signaling (Bu et al., 2017). In this study, I also showed that BBR induced mouse and 
human Bsep/BSEP expression. However, the underlying mechanism is not known. The 
overall goal of my dissertation is to determine the underlying mechanisms by which BBR 
induces mouse and human Bsep/BSEP expression, especially the roles of Nrf2 activation 
and TLR4 inhibition.  
        In my dissertation, I first determined whether BBR-induced Bsep/BSEP expression 
can lead to enhanced transport function. As expected, BBR enhanced Bsep/BSEP efflux 
function, evidenced by increased efflux of dichlorofluorescin diacetate, the selective Bsep 
substrate, out of mouse and human hepatoma cells. Therefore, BBR-induced Bsep/BSEP 
expression consequently leads to increased cellular efflux activity of Bsep/BSEP. 
        Next, I determined the involvement of Nrf2 activation in BBR-induced Bsep/BSEP 
expression. The results first showed that BBR activated Nrf2 signaling, evidenced by 
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increased nuclear translocation of Nrf2 protein and increased expression of Nqo-1/NQO-
1 and Ho-1/HO-1, two known Nrf2 target genes in mouse and human hepatoma cells. 
However, BBR apparently did not activate Nrf2 signaling in mouse liver. In addition, 
BBR increased mouse Bsep expression in both wild-type and Nrf2-null mouse livers, and 
even can activate mouse Bsep gene promoter in both presence and absence of putative 
ARE. These results indicated that Nrf2 is not essential for BBR to induce mouse Bsep 
expression. In contrast, after removal of putative ARE in human BSEP gene promoter, or 
in NRF2-silenced human hepatoma cells, BBR no longer induced human BSEP 
expression. Therefore, NRF2 activation is essential for BBR to induce human BSEP 
expression. Taken together, Nrf2/NRF2 plays important role in up-regulation of human 
BSEP, but not mouse Bsep by BBR. 
        I also investigated the impact of TLR4 inhibition on BBR-induced mouse Bsep 
expression by using TLR4-mutated C3H/HeJ mouse model. My findings demonstrated 
that pre-treatment of BBR suppressed TLR4-induced inflammation and then recovered 
Bsep expression in wild-type but not in TLR4-mutated mouse livers. In mouse hepatoma 
cells, BBR also reversed LPS-decreased Bsep expression. Because TLR4-NF-кB has 
been previously reported to suppress Bsep expression (Elferink et al., 2004; Trauner et 
al., 1998; Hartmann et al., 2002), BBR-induced mouse Bsep expression maybe via TLR4 
suppression. 
        My results further suggest that BBR is a promising therapeutic drug to manage 
cholestatic liver disease. However, to apply BBR for cholestasis therapy in patients, 
several limitations need to be taken into consideration. First, poor bioavailability of BBR 
is a big challenge. To solve this issue, silver nanoparticles containing BBR have been 
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designed to improve its bioavailability (Ling et al., 2008). Second, it has been reported 
that BBR metabolites may have similar effects as BBR does.  Therefore, it merits further 
investigation of Bsep regulation by BBR metabolites on. Third, due to the differences 
between in vivo and in vitro conditions, it is necessary to determine whether BBR 
similarly enhances Bsep efflux function in the whole animal. To perform this study, 
radiolabeled [18F] LCATD (LithoCholic Acid Triazole Derivative), which is a Bsep 
substrate with radioactivity, may be used to evaluate the in vivo Bsep efflux function after 
BBR treatment (Testa et al., 2018). Fourth, we may also consider using primary human 
hepatocytes and HepaRG cells. These cells have normal enzyme activity and transporter 
function, which are good models to investigate the effects of BBR in human livers.       
        In addition, my dissertation research also paves a way for future direction. In the 
studies proposed in Hypothesis I, the underlying mechanisms of how BBR activates 
human NRF2 signaling is not investigated.  It has been suggested that PI3K/Akt signaling 
and epigenetic gene regulation can lead to human NRF2 activation (Ref).  Therefore, 
these two signaling mechanisms can be further evaluated to determine whether they 
contribute to human NRF2 activation by BBR. In the studies proposed in Hypothesis II, I 
only reported that TLR4 repression may contribute to BBR-induced mouse Bsep 
expression. It merits further investigation, such as how TLR4 downstream signaling 
molecules, such as NF-кB or AP-1, contribute to BBR-induced mouse Bsep expression. 
Last, regulation of other bile flow-related transporters by BBR can also be investigated. 
For example, it has already been reported that Mdr2 can be induced by BBR and could be 
another potential target for cholestasis management (Guo et al., 2016).  
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        In conclusion, my dissertation demonstrates that BBR induced mouse and human 
Bsep/BSEP expression. In addition, BBR induced human BSEP expression via NRF2 
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